Effect of early diabetes on the response to norepinephrine and dopamine in pithed wistar kyoto and spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 32, Issue 6, 2010, Pages 390-394

  Hong, Enrique ^a   Huang, Fengyang ^b   Villafaa, Santiago ^c  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Diabetes; Dopamine; Hypertension; Norepinephrine; Vasopressor

Indexed keywords

DOPAMINE; HYPERTENSIVE FACTOR; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRESSOR RESPONSE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; DIABETES MELLITUS; DOPAMINE; HYPERTENSION; NOREPINEPHRINE; RATS; RATS, INBRED WKY; VASOCONSTRICTOR AGENTS;

EID: 78049424621     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641961003628544     Document Type: Article

References (40)

1. Kannel WB, Sorlie P, Gordon T. Labile hypertension: A faulty concept? The Framingham study. Circulation 1980;61:1183-1187.
2. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 2000;356:1955-1964.
3. Krolewski AS, Warram JH, Rand LI, Kahn CR Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med 1987;317(22):1390-1398.
4. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998;21 (suppl 3):C35-38.
5. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of diabetic complications in relation to risk factors. Diabetes 1986;35(12):1332-1339.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-986.
7. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications (Review). Diabetes 1994;43(6):836-841.
8. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositi-des, and sodium-potassium-ATPase in the pathogenesis of diabetic complications (Review). N Engl J Med 1987; 316(10):599-606.
9. Bravi MC, Pietrangeli P, Laurenti O, Basili S, Cassone-Faldetta M, Ferri C, De Mattia G. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997;46(10):1194-1198.
10. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89(22):11059-11063.
11. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241(19):2035-2038.
12. Sosenko JM, Breslow JL, Miettinen OS, Gabbay KH. Hyperglycemia and plasma lipid levels: A prospective study of young insulin-dependent diabetic patients. N Engl J Med 1980;302(12):650-654.
13. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1(8183):1373-1376.
14. Aromaa A, Reunanen A, Pyörälä K. Hypertension and mortality in diabetic and non-diabetic Finnish men. J Hypertens Suppl 1984;2(3):S205-207.
15. Yousif MH, Benter IF, Abul AH, Abraham S, Walther T, Akhtar S. Inhibition of Ras-GTPase signaling by FPTIII ameliorates development of cardiovascular dysfunction in diabetic-hypertensive rats. Vascul Pharmacol 2008;49(4-6):151- 157.
16. Kamata K, Kobayashi T. Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. Br J Pharmacol 1996;119(3):583-589.
17. Hong E, Villafaña S. Early diabetes in WKY and SHR produces decrease of the responses to angiotensin II and 5-HT and changes in the NO-cGMP pathway. Clin Exp Hypertens 2009;31(5):462-470.
18. Owen MP, Carrier GO. Calcium dependence of norepineph-rine-induced vascular contraction in experimental diabetes. J Pharmacol Exp Ther 1980;212(2):253-258.
19. Turlapaty PD, Lum G, Altura BM. Vascular responsiveness and serum biochemical parameters in alloxan diabetes melli-tus. Am J Physiol 1980;239(6):E412-421.
20. Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol 1986;132(1):75-78.
21. Heygate KM, Lawrence IG, Bennett MA, Thurston H. Impaired endothelium-dependent relaxation in isolated resistance arteries of spontaneously diabetic rats. Br J Pharmacol 1995;116(8):3251-3259.
22. Harrison HE, Johnson M. Vascular prostacyclin release and metabolic derangement in diabetes. Horm Metab Res Suppl 1981;11:43-49.
23. Silberbauer K, Clopath P, Sinzinger H, Schernthaner G. Effect of experimentally induced diabetes on swine vascular prostacyclin (PGI2) synthesis. Artery 1980;8(1):30-36.
24. Matsumoto T, Wakabayashi K, Kobayashi T, Kamata K. Alterations in vascular endothelial function in the aorta and mesenteric artery in type II diabetic rats. Can J Physiol Pharmacol 2004;82(3):175-182.
25. Pieper GM, Gross GJ. Oxygen free radicals abolish endothe-lium-dependent relaxation in diabetic rat aorta. Am J Physiol 1988;255(4 Pt 2):H825\H833.
26. Kamata K, Hayashi T, Umeda F. Persistence of cyclopiazonic acid-induced endothelium-dependent vasodilatation in spontaneously hypertensive and streptozotocin-induced diabetic rats. Jpn J Pharmacol 1997;73(3):247-250.
27. Griffith TM, Edwards DH, Davies RL, Harrison TJ, Evans KT. EDRF coordinates the behaviour of vascular resistance vessels. Nature 1987;329(6138):442-445.
28. Förstermann U, Dudel C, Frölich JC. Endothelium-derived relaxing factor is likely to modulate the tone of resistance arteries in rabbit hindlimb in vivo. J Pharmacol Exp Ther 1987;243(3):1055-1061.
29. Rapoport RM, Murad F. Endothelium-dependent and nitro-vasodilator-induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res 1983;9(4-5):281-296.
30. Fiscus RR. Molecular mechanisms of endothelium-mediated vasodilation. Semin Thromb Hemost 1988;14 suppl:12-22.
31. Conrad KP, Whittemore SL. NG-monomethyl-L-arginine and nitroarginine poten-tiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol 1992; 262(6 Pt 2):R1137-R1144.
32. Rand MJ, Li CG. The inhibition of nitric oxide-mediated relaxations in rat aorta and anococcygeus muscle by diphenylene iodonium. Clin Exp Pharmacol Physiol 1993;20(3): 141-148.
33. Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 2008;31(5):897-902.
34. Kobayashi T, Hayashi Y, Taguchi K, Matsumoto T, Kamata K. ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Physiol 2006;291(2): H846-53.
35. Bruschi G, Spaggiari M, Tacinelli L, Bruschi ME, Caroppo M, Cavatorta A. Regulation of arterial adrenoceptors during hypertension development in spontaneously hypertensive rats. J Hypertens Suppl 1984;2(3):S89-S93.
36. Shirasaki Y, Su C, Lee TJ, Kolm P, Cline WH Jr, Nickols GA.Endothelial modulation of vascular relaxation to nitrova-sodilators in aging and hypertension. J Pharmacol Exp Ther 1986;239(3):861-866.
37. Lee TJ, Shirasaki Y, Nickols GA.Altered endothelial modulation of vascular tone in aging and hypertension. Blood Vessels 1987;24(3):132-136.
38. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999;85(6):534-541.
39. Wu CC, Yen MH. Higher level of plasma nitric oxide in spontaneously hypertensive rats. Am J Hypertens 1999;12(5): 476-482.
40. Yen MH, Liu YC, Hong HJ, Sheu JR, Wu CC. Role of nitric oxide in lipopolysaccharide-induced mortality from spontaneously hypertensive rats. Life Sci 1997;60(15): 1223-1230